司巴丁N-氧化缺陷与异喹胍4-羟化的药物遗传学共变。
Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
作者信息
Bertilsson L, Dengler H J, Eichelbaum M, Schulz H U
出版信息
Eur J Clin Pharmacol. 1980 Feb;17(2):153-5. doi: 10.1007/BF00562624.
PMID:7371707
Abstract
Two subjects from each of the three groups of homozygous rapid, heterozygous, and homozygous non-metabolizers (N-oxidation) of sparteine received a single oral dose of debrisoquine. The urinary ratio of debrisoquine/4-hydroxy-debrisoquine, reflecting the individual's capacity to C-hydroxylate debrisoquine, was closely related to his phenotype for sparteine metabolism. This indicates that the two metabolic reactions are controlled by similar if not identical genetic factors.
摘要
来自司巴丁纯合快速代谢型、杂合代谢型和纯合非代谢型（N-氧化）三组中的每组两名受试者接受了单次口服剂量的地昔帕明。地昔帕明/4-羟基地昔帕明的尿排泄率反映了个体对去甲丙咪嗪进行C-羟基化的能力，与他的司巴丁代谢表型密切相关。这表明这两种代谢反应受相似（即便不是相同）的遗传因素控制。
Zotero 插件